Leveraged & Inverse ChannelPost-Vaccine Distribution, Mergers Will Dominate Biotech Industry ETFsBy Ben HernandezNovember 24, 2020
Tactical Allocation ChannelBullish on Biotech? The BBH ETF is Not Just a 2020 PlayBy Ben HernandezNovember 18, 2020
Tactical Allocation ChannelCan’t Get Enough Biotech Exposure in Your Portfolio?By Ben HernandezOctober 29, 2020
Thematic Investing ChannelChina’s Quest for a Covid-19 Vaccine Could Help Boost This ETFBy Ben HernandezOctober 19, 2020
Leveraged & Inverse ChannelBiotech Has Been in a Steady Uptrend Even Through Covid-19By Ben HernandezAugust 20, 2020
Innovative ETFs ChannelSmall Caps Can Offer Investors Big Opportunities Through 2020By Ben HernandezAugust 3, 2020
Tactical Allocation ChannelBig Biotech Stands Tall Amid Race for Virus VaccineBy Tom LydonJuly 17, 2020
Innovative ETFs ChannelGet Next-Level Biotechnology Exposure with the “GDNA” ETFBy Ben HernandezJuly 6, 2020
Thematic Investing ChannelThere’s Still Plenty of Opportunity for Biotech Post-CoronavirusBy Tom LydonJune 16, 2020
Tactical Allocation ChannelBiotech Benefits as Companies Race to Cure CoronavirusBy Tom LydonMay 26, 2020
Leveraged & Inverse ChannelTraders Can Look to Biotech ETFs to For a Potential Virus CureBy Ben HernandezMay 19, 2020
Tactical Allocation ChannelHow a Popular Biotech ETF Fits Into the Coronavirus Investing LandscapeBy Tom LydonMay 4, 2020
Tactical Allocation ChannelBiotech ETFs Brush Off Political Attacks on Drug PricesBy Tom LydonJanuary 21, 2020
Innovative ETFs ChannelETF of the Week: Virtus LifeSci Biotech Clinical Trials ETF (BBC) By Aaron NeuwirthDecember 12, 2019
Tactical Allocation ChannelBiotech ETFs Could Use Some Mergers & AcquisitionsBy Tom LydonMay 17, 2019
